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From 1987 to 1989 the Cancer Research Campaign (CRC) ran a
health education programme to promote the early detection of
cutaneous malignant melanoma in the general population in 6
district health authorities (DHAs) in England and 1 health board
(HB) in Scotland (Melia et al, 1995a, 1995b). This followed a
similar intervention in the west of Scotland (MacKie and Hole,
1992) involving the local media, leaflets and posters. The Scottish
intervention was reported to have led to a reduction in mortality
from melanoma in women, but not men, following a decrease in
the incidence rate for thick melanomas (Breslow ≥ 3.5 mm). 
Results from 2 CRC study areas did not indicate that the inter-
vention had led to a reduction in the incidence rate of thick
melanomas (Whitehead et al, 1989; Healsmith et al, 1994; Herd
et al, 1995). However, the follow-up period was only up to 3 years,
and the value of using thick melanomas as a surrogate measure for
melanoma mortality is uncertain. 
The purpose of this paper is to report the effects of the interven-
tion on annual and cumulative mortality rates for melanoma. The
advantage of the latter is that it excludes deaths in cases diagnosed
before the start of the intervention which could not therefore have
benefited (Tabar et al, 1985; Moss et al, 1999). The rates were
compared between the intervention areas and 2 groups of compar-
ison areas elsewhere in England and Scotland, with data collected
up to 9 years after the intervention. In addition, trends in the
annual mortality rates for melanoma were compared between the 3
groups of areas and with England and Wales, similar to the
analyses conducted in Scotland. 
METHODS 
The health education programme 
The intervention used the CRC Mole Watcher leaflet (Whitehead
et al, 1989; Williams et al, 1990; Healsmith et al, 1994; Herd et al,
1995) which provided advice about the early signs of melanoma
based on a 7 point checklist (MacKie, 1989), and encouraged early
reporting of suspicious lesions to general practitioners (GPs). The
leaflet did not advise on regular self-screening. The main thrust of
the intervention was in the summer of 1987, and it was then main-
tained with some variability until the summer of 1989. The inter-
vention areas had been selected because local hospital-based
registers already existed to collect information on melanoma. The
CRC funded a pigmented lesion clinic (PLC) in each area from
1987 to 1989 to help with the increase in hospital referrals, but
dermatology clinics also continued to receive referrals (Osborne
et al, 1998). 
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The age at death in the analyses was restricted to 15 to 74 years
because of the low incidence of melanoma at younger ages, and
increased risk of competing causes of death at older ages, respec-
tively. Results were compared between the 7 intervention areas, areas
in the same regional health authorities as the intervention areas (inter-
vention regions), and 5 other regional health authorities (non-inter-
vention regions). The regions selected for the last group were chosen
because, at the time of data collection, their cancer registries could
provide up-to-date data for the study period. The population sizes are
given in Table 1, and details of the study areas in the Appendix. 
Data collection on melanoma deaths 
The Office for National Statistics (ONS) and the Scottish Health
Service Information and Statistics Division (ISD) provided aggre-
gated data on melanoma mortality (ICD 172) by sex, age and area
of residence for the calculation of annual mortality rates from
1981 to 1996. 
To produce cumulative mortality rates, date of diagnosis is
necessary. The latter is not available from routinely produced
aggregated data so individual data were collected from cancer
registries. Each registry used their own coding system for cause of
death. From these systems, the underlying cause of death was
determined. Quality control checks on the coding of death by the
registries in the intervention areas were conducted by comparing
their codes with a random sample of death certificates supplied by
ONS. Agreement in general was good, but in a very small number,
the death may have been coded as the underlying cause where it
was mentioned in Part 1 of the death certificate but was not the
underlying cause. Where a date of death was recorded, but no
cause given, copies of death certificates were obtained from ONS. 
Completeness of data on deaths for both analyses was expected
to be high because it depended on the death registration system
and the routine notification of cancer deaths by ONS to the cancer
registries. No checks on completeness were made, but it is
unlikely to have varied greatly between regions. 
Outcome measures 
The annual mortality rate (the number of deaths in each year divided
by the population in that year) does not take time of diagnosis into
account and so it includes both people who were diagnosed before
and after the intervention. The cumulative mortality excludes
these people, restricting deaths to people who were diagnosed
during the intervention. However, early detection brings forward
the date of diagnosis (lead-time bias) for some people which
would otherwise have been diagnosed after the end of the inter-
vention. Consequently, a longer period than the intervention must
be used although how long depends on the lead time, which is
unknown. Deaths from the start of the campaign until the end of
1991 (a lead time of 2 years) have been included. The denomi-
nator for the cumulative mortality is the population who were
exposed to the campaign which is assumed to be the population in
1987. 
Statistical analyses 
Analyses were conducted on the full dataset, and on subgroups:
those aged < 65 because the effects of early detection may be
greater at younger ages (MacKie and Hole, 1992), and excluding
Scottish areas because the 1985 intervention may have affected
trends in melanoma. The effect of distance from the intervention
areas was initially studied by comparing areas that were adjacent
and non-adjacent to the intervention areas in those regions.
However, no consistent or significant trends were found so the
intervention regions were taken as one group. The number of
deaths, offset by the population, was analysed in Poisson regres-
sion on both annual and cumulative mortality, separately for each
sex with an age term (in 10-year age bands). 
In the analyses of the annual mortality rates, within each group
of areas, an additional variable (i) was created which estimated the
change in the slope in 1988–96 relative to that in 1981–87. To
compare the change in trends in different groups of areas, an inter-
action term (i * area) was studied in a model including all groups
of areas. Different cut off points were studied. 
For the cumulative mortality, the rate ratios are expressed rela-
tive to the non-intervention regions and to pre-intervention
mortality. Pre-intervention mortality for the years 1984 to 1986
was compiled from national statistics. The interaction between the
groups of areas and pre-and post-intervention period (1984–86 and
1987–96, respectively) was used to study the effect of the inter-
vention. A test for heterogeneity between the 7 intervention areas
was studied by treating each intervention area as an individual
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Table 1 Population sizea and annual melanoma mortality rate, age adjusted to the
European population, at the beginning of the study period (taking a 3-year average from
1981–83) in males and females 
Groups of areas
Population size* Mortality 
(millions) Rate per 105 95% CI 
Males 
Non-intervention areas 
Regions away from intervention 6.7 1.85 1.66–2.05 
Rest of intervention region 8.1 1.87 1.70–2.06 
Intervention areas  1.4 1.92 1.52–2.39
Females 
Non-intervention areas 
Regions away from intervention 6.8 1.87 1.68–2.06 
Rest of intervention region 8.3 1.70 1.54–1.87 
Intervention areas 1.5 1.43 1.09–1.83 
aPopulation in 1987 at start of intervention aged 15 to 74 years. 
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Sterne, 1997). 
RESULTS 
Annual melanoma mortality rates 
There was no significant difference in the annual mortality rate for
melanoma in males or females, age adjusted to the European popu-
lation (Office for National Statistics, 1998), between the groups of
areas at the start of the study period, 1981–1983 (Table 1). The
annual mortality rates, age adjusted to the European population
(Figures 1 and 2) appeared to show a decrease in melanoma
mortality for women in all groups of areas after 1993, and were
similar to the overall trend for England and Wales. In regression
analyses, changes in the slope of the graphs were studied using an
interaction term as described in the Methods. Different cut-off
periods from 1988 onwards were used and adjustments made for
any differences in trends between groups of areas before each cut-
off period e.g. 1981 to 1987. No significant differences were found
in the trends between areas (P > 0.30). Similar results were found
when restricted to people aged < 65 and to only those in England. 
Cumulative melanoma mortality rates 
The age-adjusted cumulative mortality rates, 1987 to 1996, in the
intervention areas, unadjusted for pre-intervention mortality rates
between the areas, showed no significant difference between
groups of areas (P > 0.30 for males and females, Table 2). After
adjusting for pre-intervention rates, there remained no significant
difference in rates for the intervention areas (P > 0.30 for males
and females separately) and the rest of the intervention regions 
(P > 0.40 for males and females separately) compared with the
regions away from the intervention. Similar results were found
after adjusting for the pre-intervention rates when restricted to
people aged < 65 and to only those in England. The results also did
not vary with different lead times. 
The heterogeneity test showed no significant difference in the
effect of the intervention on melanoma mortality between the 7
intervention areas (P = 0.30 and P = 0.45 for males and females,
respectively). 
DISCUSSION 
The CRC early detection intervention of 1987–89 did not result in a
significant reduction in the annual or cumulative mortality rates for
melanoma. Any large effect on melanoma mortality from the inter-
vention should have been detected. For example, based on the
observed cumulative mortality in the non-intervention areas, the
study had 80% power to detect a 30% reduction in males or a 28%
reduction in females in the intervention areas at the 5% significance
level. It may be that a longer period of follow-up is required to
study an effect on mortality, or the intervention may have been
more effective in subgroups of the population which could not be
studied because the number of deaths would have been too small. 
In this study some undetected benefit from the Mole Watcher
intervention cannot be ruled out, but any large effect on mortality
should have been seen. As this study was not a randomised
controlled trial, the outcome measures of mortality were compared
both before and after the start of the intervention between areas
exposed to different degrees to the intervention. Limitations asso-
ciated with the outcome measures, sources of data and exposure to
the intervention are discussed. 
Cumulative mortality has been used as an outcome measure in
randomised controlled trials of screening, and has the advantage
over annual mortality rates that it is a count of melanoma deaths
only in those cases diagnosed after the start of, and most likely to
have benefited from, the intervention (Tabar et al, 1985; Moss
et al, 1999) To overcome the problem of lead-time bias, the
melanoma cases in which deaths were counted had their period of
diagnosis extended beyond the end of the intervention to 1991. 
Unlike a screening trial in which data are collected on individ-
uals regarding their screening history, diagnosis and cause of
death, it is not feasible in mass media interventions to record for
every individual in the target population precisely who has
received and acted upon the health education provided.
Assumptions have to be made about the population exposed to the
intervention. In one survey conducted in association with the Mole
Watcher study, awareness of the leaflets and posters increased
during the intervention (Melia et al, 1995b), but this does not indi-
cate how well people understood the signs of melanoma or how
frequently they examined their skin. 
The presence of specialist registers in the intervention areas may
indicate a high level of interest in melanoma which may have had
some influence on the completeness of records and measure of
incidence of melanoma. However, the outcome measure of
melanoma mortality is less likely to be biased because of the high
ascertainment of mortality data in Britain, and the age group
studied were less likely to be affected by competing causes of
death than older age groups. The graphs of annual mortality rates
Effects of early detection on melanoma mortality 805
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Figure 1 Annual mortality rate from melanoma in males age adjusted to the
European population expressed as a three year moving average
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than those elsewhere. 
Finally, contamination of the comparison areas by health educa-
tion about early detection could have reduced the potential to
demonstrate a difference in either cumulative or annual mortality
rates between areas. General media interest in early detection is
likely to have affected all areas (Melia et al, 1994), but its effec-
tiveness at reaching all sections of the population and reducing
melanoma mortality is doubtful without the back-up of local distri-
bution of health education materials. 
Following the Scottish intervention conducted in 1985 (MacKie
et al, 1997), a reduction in the annual mortality rate for melanoma
was reported among women living in the whole of Scotland but
this occurred almost immediately after the start of the intervention.
Given the good survival for melanoma in the first 5 years, this
reduction is unlikely to have resulted from the 1985 intervention.
In this paper, the fluctuations in annual mortality are not explained
by the combined effect of the Scottish and CRC interventions, as
the results were similar when Scotland was first included and then
removed from the analyses. 
Mortality from melanoma has been falling or reaching a plateau
in several countries (Streetly and Markowe, 1995; Giles et al,
1996; MacKie et al, 1997; La Vecchia et al, 1999; Cohn-
Cedermark et al, 2000; Severi et al, 2000). In the UK these trends
first seemed to start before the interventions in 1985 and 1987
(Streetly and Markowe, 1995; MacKie et al, 1997). These are
mostly cohort effects with decreasing rates occurring in the
younger cohorts. It is impossible to claim an effect from one
specific factor although early detection may well have contributed.
In Australia (Giles et al, 1996) a greater reduction in melanoma
mortality was observed following an intensive early detection
intervention in Queensland in the 1960s than in other states. 
The lack of an effect of the intervention on cumulative mortality
occurred despite an apparent rise in the incidence rate of thin
melanomas in the intervention areas (Melia et al, 1995b). Others
have also shown an apparent rise in the rate for detection of thin
melanomas, but no evidence of a reduction in mortality (Dennis,
1999; Lipsker et al, 1999; van der Rhee et al, 1999). The rising
incidence rates pre-intervention (Whitehead et al, 1989) raise
questions about progression and over diagnosis (Edman and
Klaus, 2000). A proportion of thin melanomas may be non-
progressive (Burton and Armstrong, 1994) or lesions may be over
diagnosed as malignant (Cook et al, 1996). 
There are inherent difficulties in evaluating high-profile inter-
ventions because of the lack of a control population, and uncer-
tainty about the extent to which the target population acted
effectively on the advice about early detection. In addition the
evaluation study was set up after the intervention had taken place,
and there was a lack of data on Breslow thickness which would
enhance any study of early detection. Unlike some registries in
Australia, and the USA, Breslow thickness is not routinely
recorded by all cancer registries in the UK. Careful evaluation of
future strategies for early detection or screening is needed to
assess the effectiveness of different interventions which should
aim to reduce mortality without causing excessive increased work-
load (Doherty and MacKie, 1988; Burton et al, 1993; Melia et al,
1995a). In the UK targeted screening has been explored (Little
et al, 1995; Jackson et al, 1998; Melia et al, 2000) but there are
concerns about the accuracy and psychological effects of self-
assessment for melanoma risk (Sinclair, 1998). Screening for very
high-risk groups with a family history of melanoma might be
combined with health education to promote regular skin self-
examination in the general population (Berwick et al, 1996). Small
scale studies are needed to evaluate whether early detection of
melanoma is effective. Only then should a large-scale evaluation
study be conducted to investigate the effects on mortality, and
overall cost-effectiveness of early detection. 
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Table 2 Cumulative melanoma mortality in 1996 by sex and area 
Number of deaths Cumulative mortality rate  Rate ratio adjusted for Rate ratio adjusted for age and  
1987–1996 per 105 95% CI age 95% CI pre-campaign rates 95% CI 
Males 
Non-intervention areas 
Regions away from intervention 471 6.91 1.00 1.00 
6.30–7.56
Rest of intervention region 580 7.01 1.14 1.08 
6.45–7.60 1.02–1.27 0.91–1.29 
Intervention areas 99 6.71 0.99 1.18 
5.46–8.17 0.81–1.22 0.85–1.65 
Females 
Non-intervention areas 
Regions away from intervention 549 8.17 1.00 1.00 
7.50–8.88 
Rest of intervention region 754 9.37 0.99 0.99 
8.71–10.06 0.88–1.12 0.82–1.18 
Intervention areas 114 7.94 0.98 0.91 
6.55–9.54 0.79–1.22 0.66–1.25 
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Intervention areas: Camberwell; Edinburgh; Exeter; Leicester;
Merton, Sutton and Wandsworth; Nottingham and Southampton. 
Regions covering the intervention areas: Scotland (for
Scotland, the rest of Scotland, except Glasgow, which had an
earlier intervention in 1985, formed the intervention region rela-
tive to Edinburgh.), South East Thames, South West Thames,
South Western, Trent and Wessex. 
Non-intervention areas: East Anglia, North East Thames,
North West Thames, West Midlands and Yorkshire. 
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